Royal College of Paediatrics and Child Health

Clinical Standards ¦ Science & Research Department
5-11 Theobalds Road, London WC1X 8SH
Tel: 020 7092 6175/6166 ¦ Fax: 020 7092 6001 ¦ clinical.standards@rcpch.ac.uk

NICE Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C in children and young people

Appraisal Consultation Document (ACD)

Organisation	Comments submitted by RCPCH, with thanks to the following for commenting; • [redacted], Consultant Neonatologist,

Appraisal consultation document

Please address the following areas:

- Has all of the relevant evidence been taken into account?
- Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?
- Are the provisional recommendations sound and a suitable basis for guidance to the NHS?
- Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of gender, race, disability, age, sexual orientation, religion or belief?

Section number Indicate **section number** If relevant	**Comments** If possible, please provide evidence (citations) to support your statements
Page 42 1.1	I agree with the key conclusion of 'Peginterferon alfa-2a plus ribavirin and peginterferon alfa-2b plus ribavirin are recommended as treatment options, within their licensed indications, for children and young people with chronic hepatitis C'.
Page 44 4.3.4	I am however, slightly concerned that the systematic reviews conducted by the manufacturers and the Assessment Group identified few relevant studies in children and young people and these studies were small and of generally poor quality although this finding is not unexpected.
Page 44 4.3.5	I am reassured that the average age of entry into the trials reflected the average age of children and young people currently treated in the UK and therefore was satisfied that the trial results were largely generalisable to the UK population.

Evaluation report

Please note any comments on the evaluation report

Page number Indicate **page number** If relevant	**Comments** If possible, please provide evidence (citations) to support your statements

You may add extra rows as needed.